Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery

Abstract

The endocannabinoid system, with its intricate presence in numerous cells, tissues, and organs, offers a compelling avenue for therapeutic interventions. Central to this system are the cannabinoid receptors 1 and 2 (CB1R and CB2R), whose ubiquity can introduce complexities in targeted treatments due to their wide-ranging physiological influence. Injuries to the central nervous system (CNS), including strokes and traumatic brain injuries, induce localized pro-inflammatory immune responses, termed neuroinflammation. Research has shown that compensatory immunodepression usually follows, and these mechanisms might influence immunity, potentially affecting infection risks in patients. As traditional preventive treatments like antibiotics face challenges, the exploration of immunomodulatory therapies offers a promising alternative. This review delves into the potential neuroprotective roles of the cannabinoid receptors: CB1R’s involvement in mitigating excitotoxicity and CB2R’s dual role in promoting cell survival and anti-inflammatory responses. However, the potential of cannabinoids to reduce neuroinflammation must be weighed against the risk of exacerbating immunodepression. Though the endocannabinoid system promises numerous therapeutic benefits, understanding its multifaceted signaling mechanisms and outcomes remains a challenge.

Cannabinoid and Orexigenic Systems Interplay as a New Focus of Research in Alzheimer’s Disease

“…However, evidence demonstrates its expression at low levels in dopaminergic neurons, glial cells, and endothelial cells [56,57]. CB 1 R and CB 2 R exhibit seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus, showing as 44% homologous overall and as 68% homologous within the transmembrane domains [58].…”